The Appetite-Reducing Effect of Combining Leptin With a CB1 Blocker Required Serotonin Receptors

The appetite-reducing effect of combining leptin with a CB1 receptor blocker was completely abolished by blocking serotonin 5-HT1B and 5-HT2C receptors, revealing a three-way interaction between leptin, endocannabinoid, and serotonin systems in appetite control.

Wierucka-Rybak, M et al.·Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2016·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-01303Animal StudyPreliminary Evidence2016RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Previous research showed that combining leptin (a satiety hormone) with AM 251 (a CB1 receptor blocker) reduced food intake and body weight more effectively than either compound alone. This study investigated whether the serotonin system mediates this effect.

As expected, combining leptin and AM 251 for 3 days significantly reduced food intake and body weight in rats, while neither compound alone had a significant effect at the doses used.

Blocking either serotonin 5-HT1B receptors (with GR 127935) or 5-HT2C receptors (with SB 242084) completely abolished both the appetite-reducing and weight-loss effects of the leptin/AM 251 combination.

This reveals that the serotonin system is a necessary downstream mediator of the appetite-suppressing interaction between leptin and the endocannabinoid system.

Key Numbers

Leptin 100 micrograms/kg + AM 251 1 mg/kg: significant reduction in food intake and body weight over 3 days. GR 127935 (3 mg/kg) or SB 242084 (0.5 mg/kg) completely abolished these effects. Neither leptin nor AM 251 alone at these doses significantly affected food intake.

How They Did This

Male Wistar rats received simultaneous injections of leptin (100 micrograms/kg) and AM 251 (1 mg/kg) with or without serotonin receptor antagonists (GR 127935 for 5-HT1B, SB 242084 for 5-HT2C) for 3 days. Food intake and body weight were measured.

Why This Research Matters

Understanding how appetite-regulating systems interact is crucial for developing obesity treatments. The endocannabinoid system (targeted by the withdrawn drug rimonabant), leptin signaling (disrupted in obesity), and serotonin (targeted by several appetite medications) form an interconnected network. This study maps one of those connections.

The Bigger Picture

The failure of rimonabant (a CB1 blocker) as an obesity drug due to psychiatric side effects highlighted the need for more nuanced approaches to endocannabinoid-based appetite regulation. By showing that serotonin mediates the appetite effects of CB1 blockade, this study suggests that targeting the serotonin pathway downstream might achieve the metabolic benefits without the psychiatric risks of direct CB1 blockade.

What This Study Doesn't Tell Us

Rat study that may not translate directly to human appetite regulation. Three days of treatment is short and does not address long-term effects or tolerance. The serotonin antagonists used block specific receptor subtypes, but the serotonin system is complex with many interacting receptors.

Questions This Raises

  • ?Could combining low-dose serotonergic drugs with endocannabinoid modulators produce effective weight loss with fewer side effects than either approach alone?
  • ?Does chronic cannabis use (which downregulates CB1 receptors) affect serotonin-mediated appetite regulation?
  • ?Would this three-way interaction be relevant for understanding cannabis withdrawal-related appetite changes?

Trust & Context

Key Stat:
Blocking either 5-HT1B or 5-HT2C serotonin receptors completely abolished the appetite-reducing effect of leptin + CB1 blockade.
Evidence Grade:
Preliminary evidence from an animal study demonstrating a clear pharmacological interaction, though human relevance requires further investigation.
Study Age:
Published in 2016. The interaction between endocannabinoid, leptin, and serotonin systems in appetite regulation continues to be studied.
Original Title:
The inhibitory effect of combination treatment with leptin and cannabinoid CB1 receptor agonist on food intake and body weight gain is mediated by serotonin 1B and 2C receptors.
Published In:
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 67(3), 457-63 (2016)
Database ID:
RTHC-01303

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

How does the endocannabinoid system control appetite?

The endocannabinoid system promotes appetite through CB1 receptors. This study shows that its interaction with leptin (a satiety hormone) depends on serotonin signaling, revealing a three-way regulatory network controlling how much we eat.

Why does this matter for weight loss?

Direct CB1 blockers (like rimonabant) reduced appetite but caused depression. Understanding that serotonin mediates the appetite effects could enable targeting serotonin pathways instead, potentially achieving weight loss without the psychiatric side effects of CB1 blockade.

Read More on RethinkTHC

Cite This Study

RTHC-01303·https://rethinkthc.com/research/RTHC-01303

APA

Wierucka-Rybak, M; Wolak, M; Juszczak, M; Drobnik, J; Bojanowska, E. (2016). The inhibitory effect of combination treatment with leptin and cannabinoid CB1 receptor agonist on food intake and body weight gain is mediated by serotonin 1B and 2C receptors.. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 67(3), 457-63.

MLA

Wierucka-Rybak, M, et al. "The inhibitory effect of combination treatment with leptin and cannabinoid CB1 receptor agonist on food intake and body weight gain is mediated by serotonin 1B and 2C receptors.." Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2016.

RethinkTHC

RethinkTHC Research Database. "The inhibitory effect of combination treatment with leptin a..." RTHC-01303. Retrieved from https://rethinkthc.com/research/wierucka-rybak-2016-the-inhibitory-effect-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.